Compare Datadog Inc (DDOG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Gilead Sciences, Inc. — how do they compare? Datadog Inc trades at $279.75 (market cap $98.31B), while Gilead Sciences, Inc. trades at $149 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Gilead Sciences, Inc. for 111 Days on average.
| DDOG | GILD | |
|---|---|---|
Market Cap | $98.31B | $182.40B |
Volume | 2,936,660 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $288.15 | $155.80 |
52-Week Low | $102.62 | $116.74 |
Typical Hold Time | 76 Days | 111 Days |
Enterprise Value | $94.61B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $271.34, down 2.48% on the day, but maintains a bullish technical outlook with strong support near $269. The company continues to deliver robust revenue growth, reaching $3.43B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with a consensus price target of $276.10, though high valuation multiples like a P/E of 547.6 signal premium pricing. Recent news highlights accelerating AI and enterprise customer expansion as key growth drivers.
The outlook for DDOG is favorable given its consistent earnings beats and strategic positioning in cloud observability and AI infrastructure. However, investors face risks from elevated valuations, negative net cash flow, and competitive pressures in the cloud software sector. The stock's proximity to its consensus target suggests limited near-term upside, making execution on growth initiatives critical for further appreciation.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
